BridgeBio is significantly advanced its development of a new treatment for cardiac amyloidosis, employing the investigational drug. Initial clinical data indicates significant improvements for patients suffering with https://attruby847171.blogginaway.com/42928417/company-improves-cardiac-amyloidosis-therapy-with-attruby